Can new biomarkers transform adrenal cancer treatment?
NCT ID NCT05754892
First seen Apr 04, 2026 · Last updated Jun 09, 2026 · Updated 6 times
Summary
This study aims to bring new molecular markers into routine care for patients with rare adrenal cancers. Researchers will check if these markers can be delivered within 3 months after surgery and if they provide useful information to guide treatment. About 450 adults with adrenal tumors will take part. The goal is to see if these markers help doctors make better decisions and improve patient outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GH Paris Centre, Assistance Publique - Hôpitaux de Paris
RECRUITINGParis, 75014, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.